Geovax Labs, Inc. (GOVX)
NASDAQ:GOVX
Want to see GOVX full AI Analyst Report?
Top Page
GeoVax Labs
(NASDAQ:GOVX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.50
▼(-57.98% Downside)
Action:Reiterated
Date:06/10/26
The score is driven primarily by very weak financial performance (large losses, falling revenue, and significant cash burn), reinforced by a bearish technical trend with the stock trading below major moving averages. A small liquidity boost from the financing event is offset by dilution risk, and valuation provides limited support due to ongoing unprofitability.
Positive Factors
Modest reported leverage
Reported debt-to-equity around 0.8 and low absolute debt provide the company with comparatively greater financial flexibility versus many early-stage biotech peers. This structural balance-sheet characteristic reduces short-term insolvency risk and supports continuing R&D funding before additional dilutive raises are strictly required.
Negative Factors
Heavy cash burn
Persistent negative operating and free cash flow of roughly -$19M TTM indicates the company cannot self-fund development. This structural cash burn necessitates repeated external financing, increases dilution risk over time, and constrains ability to sustain multiple clinical programs without strategic partnerships or substantial new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest reported leverage
Reported debt-to-equity around 0.8 and low absolute debt provide the company with comparatively greater financial flexibility versus many early-stage biotech peers. This structural balance-sheet characteristic reduces short-term insolvency risk and supports continuing R&D funding before additional dilutive raises are strictly required.
Read all positive factors
GeoVax Labs (GOVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.98M
Dividend YieldN/A
Average Volume (3M)10.23M
Price to Earnings (P/E)―
Beta (1Y)3.47
Revenue Growth-84.76%
EPS Growth79.01%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-21.67
Shares Outstanding5,210,465
10 Day Avg. Volume1,085,598
30 Day Avg. Volume10,225,484
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.07
Price to Sales (P/S)1.65
P/FCF Ratio-0.19
Enterprise Value/Market Cap0.04
Enterprise Value/Revenue0.30
Enterprise Value/Gross Profit0.29
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$10.00Price Target Upside180.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-9.28
Revenue Forecast (FY)N/A
GeoVax Labs Business Overview & Revenue Model
Company Description
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modifi...
How the Company Makes Money
null...
GeoVax Labs Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements in the development and potential expedited approval of key vaccine candidates, along with increased industry interest and collaboration potential. However, financial challenges, including decreased revenue and increased net loss, present concerns. Overall, the positive development news is somewhat tempered by the financial performance.Positive Updates
Expedited Development Path for GEO-MVA
GeoVax received guidance from the European Medicines Agency to bypass Phase I and Phase II trials for GEO-MVA, proceeding directly to a Phase III immuno-bridging trial, potentially accelerating marketing authorization and revenue generation.
Negative Updates
Revenue Decline
Revenues decreased to $2.5 million in the first nine months of 2025 compared to $3.1 million in 2024, primarily due to the termination of the BARDA Project NextGen contract.
Read all updates
Q3-2025 Updates
Positive
Negative
Expedited Development Path for GEO-MVA
GeoVax received guidance from the European Medicines Agency to bypass Phase I and Phase II trials for GEO-MVA, proceeding directly to a Phase III immuno-bridging trial, potentially accelerating marketing authorization and revenue generation.
Read all positive updates
Company Guidance
During the GeoVax Third Quarter 2025 Corporate Update Call, the company provided several key metrics regarding its progress and strategic initiatives. GeoVax highlighted its vaccine candidate GEO-MVA, which received expedited development guidance from the European Medicines Agency (EMA) to bypass Phase I and Phase II trials and proceed directly to a Phase III immuno-bridging trial. This advancement could lead to earlier marketing authorization and revenue generation. Financially, for the nine months ended September 30, 2025, GeoVax reported revenues of $2.5 million, a decrease from $3.1 million in 2024, primarily due to the termination of the BARDA Project NextGen contract. Research and development expenses decreased to $15.1 million from $16.1 million in the previous year, while general and administrative expenses increased to $4.6 million from $3.8 million. The company's net loss for the quarter was $6.3 million, slightly higher than $5.8 million in 2024. GeoVax remains focused on advancing its GEO-MVA vaccine and other product candidates, with significant interest in partnerships and collaborations to support development and commercialization.GeoVax Labs Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 852.28K | 2.49M | 3.95M | 0.00 | 81.53K | 385.50K |
| Gross Profit | 886.00K | 2.49M | 3.86M | -20.72M | -9.04M | 385.50K |
| EBITDA | -21.48M | -21.40M | -24.88M | -25.89M | -13.96M | -18.53M |
| Net Income | -21.37M | -21.46M | -24.99M | -25.97M | -14.02M | -18.57M |
Balance Sheet | ||||||
| Total Assets | 2.98M | 6.34M | 8.16M | 9.28M | 31.35M | 11.80M |
| Cash, Cash Equivalents and Short-Term Investments | 1.27M | 3.09M | 5.51M | 6.45M | 27.61M | 11.42M |
| Total Debt | 394.57K | 843.17K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.49M | 2.52M | 3.11M | 3.52M | 4.75M | 7.43M |
| Stockholders Equity | 493.77K | 3.83M | 5.05M | 5.76M | 26.60M | 4.36M |
Cash Flow | ||||||
| Free Cash Flow | -19.06M | -21.50M | -24.70M | -25.22M | -19.16M | -11.24M |
| Operating Cash Flow | -19.05M | -21.47M | -24.68M | -25.17M | -19.03M | -11.20M |
| Investing Cash Flow | -10.72K | -27.61K | -20.65K | -48.95K | -134.26K | -47.72K |
| Financing Cash Flow | 12.89M | 19.08M | 23.75M | 4.06M | 35.35M | 12.78M |
GeoVax Labs Technical Analysis
Negative
3.57
Price Trends
1.57
Negative
1.71
Negative
6.35
Negative
Market Momentum
-0.18
Positive
43.48
Neutral
22.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOVX, the sentiment is Negative. The current price of 3.57 is above the 20-day moving average (MA) of 1.89, above the 50-day MA of 1.57, and below the 200-day MA of 6.35, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 43.48 is Neutral, neither overbought nor oversold. The STOCH value of 22.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOVX.
GeoVax Labs Risk Analysis
GeoVax Labs disclosed 31 risk factors in its most recent earnings report. GeoVax Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GeoVax Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $14.27M | -1.63 | -22.03% | ― | -93.71% | 23.89% | |
48 Neutral | $65.36M | -5.81 | -82.34% | ― | ― | 16.07% | |
47 Neutral | $25.94M | -0.91 | -119.92% | ― | -45.35% | 58.32% | |
45 Neutral | $19.21M | -1.38 | -66.69% | ― | -45.52% | -94.82% | |
41 Neutral | $6.98M | -0.13 | -709.51% | ― | -84.76% | 79.01% | |
41 Neutral | $5.92M | ― | -246.04% | ― | ― | 54.48% |
* Healthcare Sector Average
GOVX
GeoVax Labs
1.34
-21.78
-94.20%
BLRX
Bioline RX Ltd Sponsored ADR
3.16
-1.08
-25.47%
SNGX
Soligenix
0.40
-1.30
-76.53%
LPCN
Lipocine
2.33
-0.97
-29.39%
EDSA
Edesa Biotech
7.35
5.39
275.00%
LGVN
Longeveron
0.82
-0.38
-31.67%
GeoVax Labs Corporate Events
Executive/Board ChangesPrivate Placements and FinancingShareholder Meetings
GeoVax Shareholders Back Board, Auditor and Warrant Issuances
Neutral
Jun 17, 2026
GeoVax Labs held its annual meeting of stockholders on June 17, 2026, with investors electing a seven-member board of directors and ratifying Wipfli LLP as the independent auditor for the fiscal year ending December 31, 2026. Shareholders also gav...
Business Operations and StrategyPrivate Placements and Financing
GeoVax Raises $3 Million via Private Placement Financing
Neutral
May 19, 2026
GeoVax Labs, Inc., a clinical-stage biotech focused on vaccines and immunotherapies for infectious diseases and solid tumors, is advancing its GEO-MVA mpox and smallpox vaccine toward an expedited Phase 3 trial, while progressing its Gedeptin gene...
Private Placements and Financing
GeoVax Labs Announces Warrant Inducement and Financing Move
Neutral
May 7, 2026
On May 7, 2026, GeoVax Labs entered into a warrant inducement agreement with existing institutional investors, prompting the immediate cash exercise of warrants for 501,144 shares of common stock, expected to generate about $595,000 in gross proce...
Business Operations and StrategyPrivate Placements and Financing
GeoVax Labs Boosts Liquidity Through Warrant Inducement Financing
Positive
Apr 1, 2026
On March 31, 2026, GeoVax Labs entered into a warrant inducement agreement with existing healthcare-focused institutional investors, who agreed to immediately exercise warrants for up to 634,658 common shares at a reduced price of $1.36, generatin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.